Immunitybio Inc (IBRX) 13F Holdings Overview (Q2 2026)

IBRX ranks #1493 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

412 institutions disclose a position in IBRX, but none treat it as a major bet — even Great Point Partners LLC, its most concentrated holder, allocates just 5.0% of its own portfolio to it.

Doliver Advisors, LP has added to its IBRX position for two straight quarters, increasing it by $1.6M to reach $2.0M today.

IBRX is up 10.8% today, and institutions have been net buyers of $375.6M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

IBRX reported a net loss of $992.4M over the trailing twelve months.

• Not yet profitable — net loss of $992.4M over the trailing twelve months
• Revenue grew 192.9% year over year
• Net income declined year over year, from -$367.1M to -$992.4M
• Operating cash flow was negative, using $304.9M in cash